Research ArticleArticle
Development and Validation of 3 Preliminary MRI Sacroiliac Joint Composite Structural Damage Scores In a 5-year Longitudinal Axial Spondyloarthritis Study
Marie Wetterslev, Mikkel Østergaard, Inge J. Sørensen, Ulrich Weber, Anne G. Loft, Gina Kollerup, Lars Juul, Gorm Thamsborg, Ole R. Madsen, Jakob M. Møller and Susanne J. Pedersen
The Journal of Rheumatology April 2021, jrheum.201075; DOI: https://doi.org/10.3899/jrheum.201075
Marie Wetterslev
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Mikkel Østergaard
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Inge J. Sørensen
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Ulrich Weber
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Anne G. Loft
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Gina Kollerup
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Lars Juul
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Gorm Thamsborg
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Ole R. Madsen
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Jakob M. Møller
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Susanne J. Pedersen
The Biomarkers in Spondylarthritis study (BIOSPA; ClinicalTrials.gov: ) was conducted without any financial support. The Danish Rheumatism Association supported MW with a PhD fellowship grant (R131-A5381). . Wetterslev, MD, M. Østergaard, MD, PhD, DMSc, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen; I.J. Sørensen, MD, PhD, G. Kollerup, MD, PhD, L. Juul, MD, PhD, G. Thamsborg, MD, DMSc, O.R. Madsen, MD, PhD, DMSc, S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen; U. Weber, MD, Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Soenderborg, and Department of Regional Health Research, University of Southern Denmark, Odense; A.G. Loft, MD, PhD, Department of Rheumatology, Lillebælt Hospital, Vejle, Department of Rheumatology, Aarhus University Hospital, Aarhus; J.M. Møller, PhD, Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark. MØ has received research support, consultancy fees and/or speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB; has been an advisory board member for AbbVie and Novartis; and has received research support from AbbVie, MSD, and Novartis. AGL has been a consultant and advisor for AbbVie, Eli Lilly, MSD, Novartis, Pfizer, and UCB and has received speaker fees from AbbVie, MSD, Novartis, Pfizer, and UCB. GK has received speaker fees from Eli Lilly. MW, IJS, UW, LJ, GT, ORM, and JMM declare no conflicts of interest relevant to this article. Address correspondence to Dr. M. Wetterslev, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: marie.wetterslev@regionh.dk. Accepted for publication March 31, 2021.
Article Figures & Data
Additional Files
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Development and Validation of 3 Preliminary MRI Sacroiliac Joint Composite Structural Damage Scores In a 5-year Longitudinal Axial Spondyloarthritis Study
Marie Wetterslev, Mikkel Østergaard, Inge J. Sørensen, Ulrich Weber, Anne G. Loft, Gina Kollerup, Lars Juul, Gorm Thamsborg, Ole R. Madsen, Jakob M. Møller, Susanne J. Pedersen
The Journal of Rheumatology Apr 2021, jrheum.201075; DOI: 10.3899/jrheum.201075
Development and Validation of 3 Preliminary MRI Sacroiliac Joint Composite Structural Damage Scores In a 5-year Longitudinal Axial Spondyloarthritis Study
Marie Wetterslev, Mikkel Østergaard, Inge J. Sørensen, Ulrich Weber, Anne G. Loft, Gina Kollerup, Lars Juul, Gorm Thamsborg, Ole R. Madsen, Jakob M. Møller, Susanne J. Pedersen
The Journal of Rheumatology Apr 2021, jrheum.201075; DOI: 10.3899/jrheum.201075